Hirsutism Clinical Trial
Official title:
Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
Hirsutism is defined as the excessive presence of terminal hairs in the androgen-sensitive
areas of the female body, and it is one of the frequent reasons for presenting to dermatology
outpatient clinics. Hirsutism influences 5% to 10% of women around the world and leads to
psychological problems depending on ethnic and socio-cultural factors. It also causes
material burden including medicines, cosmetic products and epilation procedures.
The differences in the real prevalence of hirsutism in the Turkish population and the
hirsutism prevalence and severity between the geographical regions of Turkey are not known.
In this study, we aimed to determine the prevalence of hirsutism in women at the reproductive
age within Turkey. The geographical regions of Turkey comprise seven regions and and all
regions were included in this study. By considering the regions where ethnic differences were
high including the east-west-south and north of our country, we aimed to find an answer to
the question of whether there were differences in terms of the prevalence and severity of
hirsutism among these regions. A comprehensive study aiming to determine the prevalence of
hirsutism in Turkey has not been conducted.
Twenty-two provinces of Turkey's seven regions and 26 hospitals from these provinces will be
included in the study. The number of samples was specified by the public health specialist on
the 2018 census figures. The Turkish population consists of 80,810,525 people according to
the data announced by the Turkish Statistical Institute in 2018. In order to determine the
prevalence in Turkey, the sample size was calculated with a confidence interval of 99% and
error margin of 1%, and the total number of individuals to be screened was designated as
5861. The number of patients to be screened via the clustering method weighted by regions was
specified as 1800 for the Marmara Region, 750 for the Aegean Region, 744 for the
Mediterranean Region, 568 for the Black Sea Region, 932 for the Central Anatolia Region, 434
for the Eastern Anatolia Region and 633 for the Southeastern Anatolia Region. The provinces
that were thought to represent each region were selected via the cluster sampling method.
During the study period, female patients aged between 18 and 45, who present to dermatology
outpatient clinics, will be examined clinically until the number of patients designated for
each study center is reached, and the hirsutism level of the patients diagnosed with
hirsutism will be determined by using the modified Ferriman-Gallwey (mFG) scoring system. In
this system, hair growth in nine regions (upper lip, chin, chest, upper back, lower back,
upper abdomen, lower abdomen, upper arms and thighs) is graded between 0 and 4. And nine
regions are scored between 0 (no terminal hairs) and 4 (excessive presence of terminal
hairs). The score above 8 is considered hirsutism. The hirsutism family history, body mass
index, menstrual cycle pattern, concomitant disease status (diabetes, hyperlipidemia,
hypertension, thyroid disease), history of medication causing body hair growth, the acne
presence and severity, presence and severity of androgenic alopecia, presence of seborrhea,
presence and localization of acanthosis nigricans, presence of acrochordon, presence of
hidradenitis suppurativa, presence of galactorrhea, presence of virilization symptoms and
presence of cushingoid symptoms of all the examined patients will be investigated and
recorded.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02103608 -
Clinical Evaluation of Silk'n Glide for Face
|
N/A | |
Not yet recruiting |
NCT00495443 -
Enhanced Safety Aesthetic Laser System
|
N/A | |
Not yet recruiting |
NCT06003062 -
Suppression of Upper Lip Hair Growth Using Novel Hemp Extract
|
||
Active, not recruiting |
NCT00145288 -
Prospective Study of Patients With Hirsutism
|
Phase 2/Phase 3 | |
Completed |
NCT00152048 -
Evaluation of Eflornithine on Facial and Forearm Skin
|
Phase 4 | |
Enrolling by invitation |
NCT01461694 -
Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00441948 -
Enhanced Safety Laser Hair Removal System
|
N/A | |
Completed |
NCT03673995 -
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
|
N/A | |
Recruiting |
NCT04979377 -
Prevalence of Hyperandrogenism in Type 1 Diabetes
|
||
Completed |
NCT02494297 -
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
|
||
Completed |
NCT00960310 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
|
Phase 1 | |
Completed |
NCT02793557 -
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
|
Phase 1/Phase 2 | |
Completed |
NCT01817894 -
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
|
Phase 4 | |
Completed |
NCT01555190 -
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone
|
N/A | |
Completed |
NCT00143052 -
Bone Status and Insulin Resistance in Hirsutism
|
N/A | |
Recruiting |
NCT01338519 -
Database Study on Patients With PCOS
|
N/A | |
Completed |
NCT00959335 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT00371930 -
Photodynamic Therapy for Permanent Hair Removal
|
Phase 1/Phase 2 |